Issue 121 • August 2022

How much does it hurt—measuring pain in clinical trials

Tracing the rise of orphan drug designations over almost 40 years

Heart failure: charting clinical trials in the past decade

In association with

Genomic projects exploit scale as clinical applications play catch-up

New studies on gene signatures and chromosomal instability using samples from large databases add insight to their clinical applicability

In association with

07/25/2022 08:59:57
  • Home | Genomic projects exploit scale
  • In this issue
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Owen Mumford Company Insight
  • Owen Mumford
  • Comment
  • Disappointing results signal setbacks for Alzheimer’s treatments
  • Heart failure: charting the clinical trial landscape in the past decade
  • Russia’s focus on domestic pharma production could shield it from sanctions
  • Delayed EMA approval: improved safety or lack of access to therapeutics?
  • CMOs and US Government invest in continuous manufacturing
  • Baxter
  • CSafe Global
  • Nipro
  • In Depth
  • Genomic projects exploit scale as clinical applications play catch-up
  • Tracing the rise of orphan drug designations over almost 40 years
  • How much does it hurt—measuring pain in clinical trials
  • Neglected tropical diseases: non-profits lead the way as private sectors lags
  • CMO Moves: Regulatory catalysts for drug manufacturing-July
  • Pfeiffer Vacuum
  • Biolife Solutions
  • In Data
  • Supply chain & logistics innovation among pharma companies
  • Hiring boom in pharmaceutical industry IoT roles
  • Regenerative medicine deals decreased in the pharma industry
  • Digitalization jobs in the pharmaceutical industry
  • Events
  • Next issue